AR113758A1 - Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo - Google Patents
Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitriloInfo
- Publication number
- AR113758A1 AR113758A1 ARP180102928A ARP180102928A AR113758A1 AR 113758 A1 AR113758 A1 AR 113758A1 AR P180102928 A ARP180102928 A AR P180102928A AR P180102928 A ARP180102928 A AR P180102928A AR 113758 A1 AR113758 A1 AR 113758A1
- Authority
- AR
- Argentina
- Prior art keywords
- metoxypiridin
- methylpropoxy
- heptan
- pyrazolo
- carbonitrile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un proceso para preparar un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, dicho proceso caracterizado porque comprende tratar un compuesto de fórmula (2) o una sal del mismo con 6-metoxinicotinaldehído y un agente reductor para formar el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762570565P | 2017-10-10 | 2017-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113758A1 true AR113758A1 (es) | 2020-06-10 |
Family
ID=64051741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102928A AR113758A1 (es) | 2017-10-10 | 2018-10-10 | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo |
Country Status (10)
Country | Link |
---|---|
US (3) | US10745419B2 (es) |
EP (1) | EP3694853B1 (es) |
JP (1) | JP6926329B2 (es) |
CN (1) | CN111263760B (es) |
AR (1) | AR113758A1 (es) |
CA (1) | CA3079019C (es) |
ES (1) | ES2949265T3 (es) |
TW (1) | TWI783057B (es) |
UY (1) | UY37927A (es) |
WO (1) | WO2019075092A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI791053B (zh) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI783057B (zh) * | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 |
CN112771043B (zh) * | 2018-09-30 | 2023-04-28 | 北京志健金瑞生物医药科技有限公司 | 取代吡唑稠环类衍生物及其制备方法和应用 |
WO2020248972A1 (en) * | 2019-06-10 | 2020-12-17 | Js Innopharm (Shanghai) Ltd | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
CN112939967A (zh) * | 2019-12-11 | 2021-06-11 | 深圳晶泰科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
CN111057075B (zh) * | 2019-12-24 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | Ret抑制剂及其制备方法 |
CN111004257B (zh) * | 2019-12-24 | 2021-06-29 | 武汉九州钰民医药科技有限公司 | 制备RET抑制剂Selpercatinib的方法 |
CN113121524B (zh) | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
NL2024731B1 (en) | 2020-01-22 | 2021-09-09 | Sonova Ag | Acoustic device with deformable shape as valve |
NL2024842B1 (en) | 2020-02-05 | 2021-09-13 | Sonova Ag | Acoustic device with sma microspring switch |
CN111302945B (zh) * | 2020-02-21 | 2023-06-13 | 上海再启生物技术有限公司 | 3-羟基-4-甲氧基-2-硝基苯甲酸的制备方法 |
CN111410662B (zh) * | 2020-03-27 | 2020-12-29 | 苏州信诺维医药科技有限公司 | 一种酪氨酸激酶抑制剂 |
TW202202501A (zh) * | 2020-04-17 | 2022-01-16 | 美商絡速藥業公司 | 結晶ret抑制劑 |
CN113880865A (zh) * | 2020-07-01 | 2022-01-04 | 上海艾力斯医药科技股份有限公司 | 吡唑[1,5-a]吡啶类化合物及其制备方法与应用 |
WO2022020279A1 (en) | 2020-07-21 | 2022-01-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of selpercatinib and process for preparation thereof |
CN114621256A (zh) * | 2020-12-11 | 2022-06-14 | 深圳众格生物科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
CN112679494B (zh) * | 2020-12-24 | 2023-05-16 | 贵州民族大学 | 一种吡唑并[1,5-a]吡啶衍生物的制备方法 |
WO2022168122A1 (en) * | 2021-02-06 | 2022-08-11 | Msn Laboratories Private Limited, R&D Center | Processes for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
CN113321668A (zh) * | 2021-06-21 | 2021-08-31 | 江苏慧聚药业有限公司 | 塞尔帕替尼的合成 |
CN113387947B (zh) * | 2021-07-12 | 2022-07-01 | 中国科学院成都生物研究所 | 调节***受体合成活性的吡唑并吡啶衍生物 |
AU2022416156A1 (en) * | 2021-12-13 | 2024-05-30 | Loxo Oncology, Inc. | Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor |
CN117229292A (zh) * | 2022-10-18 | 2023-12-15 | 药雅科技(上海)有限公司 | Ret抑制剂的制备及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR086042A1 (es) * | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (zh) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
TWI783057B (zh) * | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 |
-
2018
- 2018-10-09 TW TW107135657A patent/TWI783057B/zh active
- 2018-10-10 CA CA3079019A patent/CA3079019C/en active Active
- 2018-10-10 US US16/156,955 patent/US10745419B2/en active Active
- 2018-10-10 AR ARP180102928A patent/AR113758A1/es unknown
- 2018-10-10 ES ES18796238T patent/ES2949265T3/es active Active
- 2018-10-10 JP JP2020518676A patent/JP6926329B2/ja active Active
- 2018-10-10 EP EP18796238.6A patent/EP3694853B1/en active Active
- 2018-10-10 CN CN201880061577.XA patent/CN111263760B/zh active Active
- 2018-10-10 UY UY0001037927A patent/UY37927A/es unknown
- 2018-10-10 WO PCT/US2018/055255 patent/WO2019075092A1/en unknown
-
2020
- 2020-06-16 US US16/902,424 patent/US11098064B2/en active Active
-
2021
- 2021-08-13 US US17/401,892 patent/US11807651B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2949265T3 (es) | 2023-09-27 |
JP6926329B2 (ja) | 2021-08-25 |
UY37927A (es) | 2019-04-30 |
EP3694853A1 (en) | 2020-08-19 |
US20200308194A1 (en) | 2020-10-01 |
JP2020536084A (ja) | 2020-12-10 |
US20190106438A1 (en) | 2019-04-11 |
US20210380609A1 (en) | 2021-12-09 |
CN111263760A (zh) | 2020-06-09 |
TWI783057B (zh) | 2022-11-11 |
WO2019075092A1 (en) | 2019-04-18 |
TW201922757A (zh) | 2019-06-16 |
EP3694853B1 (en) | 2023-05-17 |
US11098064B2 (en) | 2021-08-24 |
US10745419B2 (en) | 2020-08-18 |
CA3079019C (en) | 2022-07-19 |
US11807651B2 (en) | 2023-11-07 |
CN111263760B (zh) | 2023-06-23 |
CA3079019A1 (en) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113758A1 (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
IL268960A (en) | 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome | |
MA43745A (fr) | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer | |
NZ751418A (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
CO2017001035A2 (es) | “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios | |
ES2969145T3 (es) | Derivado de pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalina para su uso en el tratamiento de trastornos del CNS | |
MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
NZ732441A (en) | Solid forms of an ask1 inhibitor | |
NZ728392A (en) | High dosage strength tablets of rucaparib | |
PE20181345A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer | |
CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
CL2015003068A1 (es) | Formulaciones farmacéuticas, procesos, formas sólidas y métodos para el uso relacionado con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona | |
PH12016502307A1 (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
MX2017001757A (es) | Derivados de dihidropteridinona y sus usos. | |
NI201800071A (es) | Compuestos de isoindol | |
CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
PT3500571T (pt) | Compostos de imidazo[1,2-a] piridina, composições que os compreendem, métodos para o uso no tratamento de doenças e seus métodos de preparação | |
PE20170523A1 (es) | Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida | |
ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
EA032654B9 (ru) | [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |